Navigation Links
Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC
Date:11/3/2010

LA JOLLA, CA--The Salk Institute for Biological Studies and Columbia University Medical Center have been awarded a $15 million grant by The Leona M. and Harry B. Helmsley Charitable Trust, establishing a collaborative program to fast-track the use of induced pluripotent stem (iPS) cells to gain new insight into disease mechanisms and screen for novel therapeutic drugs.

"Stem cell research is of immense importance to the future of biomedical research and will have a major impact in treating and preventing devastating diseases," said Fred H. Gage, Ph.D., a professor in the Laboratory for Genetics at the Salk Institute and the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases.

"The funding from The Helmsley Trust will accelerate and deepen our research efforts in stem cell biology, already an area of strength at the Salk Institute. In addition, this funding allows researchers at the Salk to join forces with outstanding researchers at Columbia University in a synergistic enterprise that will bring stem cell research closer to fulfilling its promise," he said.

The ability to reprogram adult human cells into iPS cells, which by all appearances look and act like embryonic stem cells, creates a unique opportunity to study human disease in revolutionary ways. After taking a few skin cells from patients, researchers can generate iPS cells and differentiate them into the type of tissue where a disease is manifest.

Over the course of the three-year grant, the Salk will develop a stem cell bank of well-characterized iPS cells derived from patients suffering from debilitating neurological, cardiac and hematological conditions. Both institutions will use these cell lines and other stem cell-based tools to generate the cell types (nerve cells, muscle, blood cells and other tissues) affected in a wide range of diseases, and to determine the molecular causes of disease phenotypes.

These cell-based models of disease will allow investigators from both institutions to screen at Columbia tens of thousands of chemical compounds to uncover novel drug therapies for hitherto untreatable diseases. The grant will therefore create a pipeline of new models and molecules that will start from individual patients and create new avenues back to the clinic.

Christopher E. Henderson, Ph.D., Director of the Columbia Stem Cell Initiative, and Co-Director of the Columbia Motor Neuron Center, said, "Although much public interest has been focused on the use of stem cells for tissue replacement, we and our collaborators at the Salk believe that in many clinical areas their major benefit will be to allow us to model diseases in the culture dish. Such cell-based models can generate new knowledge about the disease process itself, while also opening the way to high-throughput screening for test drug candidates."

Henderson added, "The Helmsley Trust support at Columbia will be focused on freeing up two key bottlenecks in this process. It will fund new protocols to allow scientists to transform stem cells into specific classes of differentiated cells, and will help support a facility that will allow researchers with a disease model to perform drug screening on a scale inaccessible in their own laboratories."

"The Helmsley Trust is showing great vision by investing in two scientific groups operating at the leading edge of stem cell research," said Salk Institute President William R. Brody. "We are deeply grateful to the trustees and look forward to a very fruitful collaboration with our Columbia University colleagues."

"The generosity of The Helmsley Trust enables research that ultimately may lead to prevention or treatment of diseases that currently have no cure," said Lee Goldman, M.D., Dean of the Faculties of Health Sciences and Medicine and Executive Vice President for Health and Biomedical Sciences at Columbia University Medical Center. "We look forward to working with our collaborators at the Salk Institute and delivering on the promise of stem cell research."

John Codey, Trustee of The Helmsley Trust stated, "We are excited to bring together two world-class institutions to work collaboratively from the bench to the bedside in diseases including Alzheimer's, ALS and Parkinson's Disease. We hope this work will help advance this important work in these and other diseases."


'/>"/>

Contact: Kat Kearney
kearney@salk.edu
858-453-410-01226
Salk Institute
Source:Eurekalert  

Related biology news :

1. Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK
2. NIH and Wellcome Trust announce partnership to support population-based genome studies in Africa
3. Entrust Credentialing Services - A New End-to-End, SAAS Approach for Identity-Based Smartcards
4. Entrust Technology, Expertise Called on for Malaysian ePassport Project
5. Wellcome Trust funds dengue fever research in Leuven
6. Securing biological select agents and toxins will require developing a culture of trust
7. Arthritis Foundation of India Trust named winner of 2009 IOF Linda Edwards Memorial Award
8. Trust in a teardrop
9. Faculty of 1000 praised by Wellcome Trust
10. Entrusts New Code-Signing Certificates Enhance Trust in Applications, Software Developers
11. Public trust doctrine could aid management of US oceans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Helmsley Charitable Trust awards more than $15 million to Salk Institute-CUMC
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 According ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market ... 9.6% from 2016 to 2022. In 2015, Asia-Pacific dominated ... both public and private sectors. Continue Reading ... ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 2017 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its unaudited financial results for the third quarter and ... 31, 2016. Third Quarter of Fiscal 2017 ... of fiscal 2017 increased by 18.6% to RMB200.9 million ...
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
Breaking Biology Technology: